The latest app from the Navify decision support portfolio, recently released by Roche, Basel, Switzerland, in collaboration with GE Healthcare, Chicago, Ill, embeds the latest clinical practice guidelines from the National Comprehensive Cancer Network, covering the four most common cancers within the Navify tumor board: breast, colorectal, non-small cell lung, and prostate cancers.
When a case is opened, the app identifies the appropriate guidelines based on the patient’s cancer type. Clinicians can then select the intended pathway, click through the digitized decision tree or flow chart, and personalize steps for the individual patient. The pathway is accessible to all tumor board participants and can be exported for inclusion in the practice’s electronic medical record system, sent to patients, or submitted for reimbursement approval by payers.
Guidelines for clinical practice help explain a disease and determine the optimal evidence-based treatment for individuals based on their age, diagnosis, disease stage, and other factors. In addition, clinical guidelines contribute to care management by promoting practice conformity and reducing costs.
When a case is opened, the app identifies the appropriate guidelines based on the patient’s cancer type. Clinicians can then select the intended pathway, click through the digitized decision tree or flow chart, and personalize steps for the individual patient.
NCCN guidelines are updated continuously as medical knowledge advances. At the same time, with healthcare providers moving toward more value-based care and respective payment models, clinicians face an increasing need to adhere to proven guidelines. By digitizing the guidelines process, alerting users about new and updated guidelines in real time, and making the revised pathway available as part of the holistic patient dashboard, the Navify guidelines app ensures that oncology care teams have access to the latest information. The app also facilitates documentation and ensures that clinicians are aligned on each patient’s care.
“The Navify guidelines app provides clinicians with peace of mind that the latest clinical guidance has been considered in treatment decisionmaking and monitoring,” says Thomas Schinecker, CEO of Roche Diagnostics. “The ability to facilitate and track guidelines adherence, personalization, and documentation supports evidence-based care for patients around the globe. This latest addition to the Navify ecosystem marks another step in supporting the move toward truly individualized care.”
“Digitized guidelines available at point-of-care through clinical decision support software such as the Navify guidelines app help advance our mission of improving and facilitating quality, effective, efficient, and accessible cancer care so patients can live better lives,” says Robert W. Carlson, MD, CEO of NCCN.
The Navify guidelines app is available in Australia, Canada, Hong Kong, Japan, Korea, New Zealand, Singapore, Taiwan, and the United States.
For further information, visit Roche.
